Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Mint-Solifenacin (02443171), Mint-Solifenacin (02443198). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
SOLIFENACIN SUCCINATE
All products: Limited Use (codes 290)
Other products in the same Health Canada class (G04B, G04BD) — coverage varies; not interchangeable
- Darifenacin (Enablex): limited Use 290
- Tolterodine l (Detrol LA): limited Use 290
- Trospium chloride (Trosec): limited Use 290, Not a benefit
- Sildenafil (Revatio): not a benefit
Ach-Solifenacin Succinate · DIN 02439344 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Solifenacin Succinate · DIN 02439344
Manufacturer: Accord Healthcare Inc.; listing date 2023-05-31
Health Canada: Marketed since 2023-03-20 · brand ACH-SOLIFENACIN SUCCINATE · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Accord healthcare inc · schedule Prescription
Ach-Solifenacin Succinate: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92372 · Verify on the e-Formulary ↗ (DIN 02439344)
Source record
DIN 02439344: Ach-Solifenacin Succinate
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id ACH
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02439344
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92372
Interchangeable products
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: active shortage (reported 2024-05-09, last updated 2024-05-10) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02439344
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Solifenacin · DIN 02446375 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Solifenacin · DIN 02446375
Manufacturer: Auro Pharma Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-01-04 · brand AURO-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Auro pharma inc · schedule Prescription
Auro-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93171 · Verify on the e-Formulary ↗ (DIN 02446375)
Source record
DIN 02446375: Auro-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id AUR
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446375
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93171
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02446375
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Solifenacin Succinate · DIN 02428911 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Solifenacin Succinate · DIN 02428911
Manufacturer: Jamp Pharma Corporation; listing date 2016-07-28
Health Canada: Marketed since 2024-01-25 · brand JAMP SOLIFENACIN SUCCINATE · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp Solifenacin Succinate: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91336 · Verify on the e-Formulary ↗ (DIN 02428911)
Source record
DIN 02428911: Jamp Solifenacin Succinate
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428911
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91336
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02428911
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Solifenacin · DIN 02417723 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Solifenacin · DIN 02417723
Manufacturer: Pharmascience Inc.; listing date 2016-01-28
Health Canada: Marketed since 2015-10-28 · brand PMS-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Pharmascience inc · schedule Prescription
PMS-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90235 · Verify on the e-Formulary ↗ (DIN 02417723)
Source record
DIN 02417723: PMS-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id PMS
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417723
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90235
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: resolved shortage (ended 2025-05-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02417723
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PRZ-Solifenacin · DIN 02493039 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PRZ-Solifenacin · DIN 02493039
Manufacturer: Pharmaris Canada Inc.; listing date 2021-02-26
Health Canada: Marketed since 2020-11-13 · brand PRZ-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Pharmaris canada inc · schedule Prescription
PRZ-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98302 · Verify on the e-Formulary ↗ (DIN 02493039)
Source record
DIN 02493039: PRZ-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id PRZ
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02493039
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98302
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02493039
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Solifenacin · DIN 02437988 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Solifenacin · DIN 02437988
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2016-02-25
Health Canada: Marketed since 2019-12-11 · brand TARO-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Sun pharma canada inc · schedule Prescription
Ran-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92234 · Verify on the e-Formulary ↗ (DIN 02437988)
Source record
DIN 02437988: Ran-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id RAN
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437988
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92234
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: resolved shortage (ended 2024-10-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02437988
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Solifenacin · DIN 02399032 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Solifenacin · DIN 02399032
Manufacturer: Sandoz Canada Inc.; listing date 2015-11-26
Health Canada: Marketed since 2015-09-30 · brand SANDOZ SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88394 · Verify on the e-Formulary ↗ (DIN 02399032)
Source record
DIN 02399032: Sandoz Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id SDZ
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399032
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88394
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: resolved shortage (ended 2026-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399032
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Solifenacin · DIN 02458241 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Solifenacin · DIN 02458241
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2016-11-03 · brand SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Sanis health inc · schedule Prescription
Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94535 · Verify on the e-Formulary ↗ (DIN 02458241)
Source record
DIN 02458241: Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458241
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94535
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: resolved shortage (ended 2025-01-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02458241
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Solifenacin · DIN 02397900 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Solifenacin · DIN 02397900
Manufacturer: Teva Canada Limited; listing date 2015-09-30
Health Canada: Marketed since 2015-07-30 · brand TEVA-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Teva canada limited · schedule Prescription
Teva-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88283 · Verify on the e-Formulary ↗ (DIN 02397900)
Source record
DIN 02397900: Teva-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id TEV
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397900
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88283
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: resolved shortage (ended 2024-06-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397900
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Vesicare · DIN 02277263 · 5mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Vesicare · DIN 02277263
Manufacturer: Astellas Pharma Canada Inc.; listing date 2011-12-15
Health Canada: Marketed since 2006-06-23 · brand VESICARE · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Astellas pharma canada inc · schedule Prescription
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76292 · Verify on the e-Formulary ↗ (DIN 02277263)
Source record
DIN 02277263: Vesicare
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id ASE
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.6892; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02277263
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76292
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Shortage status: discontinued (2025-12-17, reported by ASTELLAS PHARMA CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02277263
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Solifenacin Succinate · DIN 02439352 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Solifenacin Succinate · DIN 02439352
Manufacturer: Accord Healthcare Inc.; listing date 2023-05-31
Health Canada: Marketed since 2023-03-20 · brand ACH-SOLIFENACIN SUCCINATE · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Accord healthcare inc · schedule Prescription
Ach-Solifenacin Succinate: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92373 · Verify on the e-Formulary ↗ (DIN 02439352)
Source record
DIN 02439352: Ach-Solifenacin Succinate
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id ACH
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02439352
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92373
Interchangeable products
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: active shortage (reported 2025-05-30, last updated 2025-05-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02439352
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Solifenacin · DIN 02446383 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Solifenacin · DIN 02446383
Manufacturer: Auro Pharma Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-01-04 · brand AURO-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Auro pharma inc · schedule Prescription
Auro-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93172 · Verify on the e-Formulary ↗ (DIN 02446383)
Source record
DIN 02446383: Auro-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446383
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93172
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02446383
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Solifenacin Succinate · DIN 02428938 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Solifenacin Succinate · DIN 02428938
Manufacturer: Jamp Pharma Corporation; listing date 2016-07-28
Health Canada: Marketed since 2024-01-25 · brand JAMP SOLIFENACIN SUCCINATE · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Jamp pharma corporation · schedule Prescription
Jamp Solifenacin Succinate: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91337 · Verify on the e-Formulary ↗ (DIN 02428938)
Source record
DIN 02428938: Jamp Solifenacin Succinate
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428938
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91337
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: resolved shortage (ended 2026-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02428938
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Solifenacin · DIN 02417731 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Solifenacin · DIN 02417731
Manufacturer: Pharmascience Inc.; listing date 2016-01-28
Health Canada: Marketed since 2015-10-28 · brand PMS-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Pharmascience inc · schedule Prescription
PMS-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90236 · Verify on the e-Formulary ↗ (DIN 02417731)
Source record
DIN 02417731: PMS-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417731
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90236
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: resolved shortage (ended 2025-05-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02417731
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PRZ-Solifenacin · DIN 02493047 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PRZ-Solifenacin · DIN 02493047
Manufacturer: Pharmaris Canada Inc.; listing date 2021-02-26
Health Canada: Marketed since 2020-11-13 · brand PRZ-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Pharmaris canada inc · schedule Prescription
PRZ-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98303 · Verify on the e-Formulary ↗ (DIN 02493047)
Source record
DIN 02493047: PRZ-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id PRZ
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02493047
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98303
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02493047
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Solifenacin · DIN 02437996 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Solifenacin · DIN 02437996
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2016-02-25
Health Canada: Marketed since 2019-12-11 · brand TARO-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Sun pharma canada inc · schedule Prescription
Ran-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92235 · Verify on the e-Formulary ↗ (DIN 02437996)
Source record
DIN 02437996: Ran-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id RAN
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437996
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92235
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: resolved shortage (ended 2026-06-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02437996
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Solifenacin · DIN 02399040 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Solifenacin · DIN 02399040
Manufacturer: Sandoz Canada Inc.; listing date 2015-11-26
Health Canada: Marketed since 2015-09-30 · brand SANDOZ SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88395 · Verify on the e-Formulary ↗ (DIN 02399040)
Source record
DIN 02399040: Sandoz Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id SDZ
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399040
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88395
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: resolved shortage (ended 2026-08-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399040
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Solifenacin · DIN 02458268 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Solifenacin · DIN 02458268
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2016-11-03 · brand SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Sanis health inc · schedule Prescription
Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94536 · Verify on the e-Formulary ↗ (DIN 02458268)
Source record
DIN 02458268: Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458268
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94536
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: Reversed (report reversed by the reporter); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02458268
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Solifenacin · DIN 02397919 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Solifenacin · DIN 02397919
Manufacturer: Teva Canada Limited; listing date 2015-09-30
Health Canada: Marketed since 2015-07-30 · brand TEVA-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Teva canada limited · schedule Prescription
Teva-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88284 · Verify on the e-Formulary ↗ (DIN 02397919)
Source record
DIN 02397919: Teva-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id TEV
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397919
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88284
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: resolved shortage (ended 2025-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397919
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Vesicare · DIN 02277271 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Vesicare · DIN 02277271
Manufacturer: Astellas Pharma Canada Inc.; listing date 2011-12-15
Health Canada: Marketed since 2006-06-23 · brand VESICARE · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Astellas pharma canada inc · schedule Prescription
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76293 · Verify on the e-Formulary ↗ (DIN 02277271)
Source record
DIN 02277271: Vesicare
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id ASE
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.6892; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02277271
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76293
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Shortage status: discontinued (2025-12-17, reported by ASTELLAS PHARMA CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02277271
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Solifenacin · DIN 02424339 · 5mg · tablet
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Solifenacin · DIN 02424339
Manufacturer: Jamp Pharma Corporation; listing date 2016-02-25
Health Canada: Dormant since 2024-07-31 · brand JAMP-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90904 · Verify on the e-Formulary ↗ (DIN 02424339)
Source record
DIN 02424339: Jamp-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424339
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90904
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: resolved shortage (ended 2024-04-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02424339
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-07-31 — choose a marketed DIN from the same-category list.
Jamp-Solifenacin · DIN 02424347 · 10mg · tablet
Limited Use — Reason for Use code 290 requiredDormant since 2024-07-31 · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Solifenacin · DIN 02424347
Manufacturer: Jamp Pharma Corporation; listing date 2016-02-25
Health Canada: Dormant since 2024-07-31 · brand JAMP-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90905 · Verify on the e-Formulary ↗ (DIN 02424347)
Source record
DIN 02424347: Jamp-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 960; item number 2280; lccId 00218; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424347
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90905
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Vesicare · DIN 02277271 · $0.3041
Shortage status: resolved shortage (ended 2024-04-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02424347
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-07-31 — choose a marketed DIN from the same-category list.
Act Solifenacin · DIN 02422239 · 5mg · tablet
Limited Use — Reason for Use code 290 required; Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.Discontinued 2018-04-30 · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required; Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.
Write on scriptLU code 290 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Act Solifenacin · DIN 02422239
Manufacturer: Actavis Pharma Company; listing date 2015-11-26
Health Canada: Cancelled post market since 2018-04-30 · brand ACT SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Actavis pharma company · schedule Prescription
Act Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90694 · Verify on the e-Formulary ↗ (DIN 02422239)
Source record
DIN 02422239: Act Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id ACV
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02422239
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90694
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02422239
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.
Apo-Solifenacin · DIN 02423375 · 5mg · tablet
Limited Use — Reason for Use code 290 required; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued 2025-04-17 · checked 2026-09-19
StatusLimited Use — Reason for Use code 290 required; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptLU code 290 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Solifenacin · DIN 02423375
Manufacturer: Apotex Inc.; listing date 2018-09-27
Health Canada: Cancelled post market since 2025-04-17 · brand APO-SOLIFENACIN · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Apotex inc · schedule Prescription
Apo-Solifenacin: Formulary list price $0.3041/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90810 · Verify on the e-Formulary ↗ (DIN 02423375)
Source record
DIN 02423375: Apo-Solifenacin
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3041; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423375
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90810
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Vesicare · DIN 02277263 · $0.3041
Shortage status: discontinued (2019-09-19, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423375
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.